» Articles » PMID: 27591925

Patients' Perspectives on Newborn Screening for Later-onset Lysosomal Storage Diseases

Overview
Journal Mol Genet Metab
Specialty Endocrinology
Date 2016 Sep 5
PMID 27591925
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Lysosomal storage diseases (LSDs) are an individually rare but collectively common group of hereditary, progressive, multi-systemic disorders. Recent technological advances have brought newborn screening (NBS) for LSDs to attention in the United States. However, many LSD symptoms present in later childhood or adulthood, with a wide spectrum of severity. Because late-onset symptoms stray from the traditional NBS model, healthcare providers have expressed concerns about potential harm to patients and/or their families. In this study, 47 individuals with Fabry disease (FD), 22 with Gaucher disease (GD), and 22 with late-onset Pompe disease (LOPD) were surveyed regarding how their life might have been impacted by NBS. Of the 91 participants, none had symptoms at birth and 42 (46.7%) were symptom-free until adulthood. Over half (52.8%) were diagnosed ≥5years from symptom onset; of these, significantly more had FD (60%) or LOPD (63.6%) than GD (23.8%). However, length of diagnostic odyssey was not significantly correlated with opinion on NBS. Most participants either strongly agreed (45%) or agreed (33.3%) with NBS for their condition, with no significant differences between diseases. Opinions on NBS were correlated with participants' opinions on whether NBS would have resulted in better current health, but uncorrelated with disease severity or current life satisfaction. Significantly more participants with FD (42.6%) and LOPD (63.6%) than GD (13.6%) felt they would have greater life satisfaction had they been diagnosed as a newborn (p=0.007). Almost half (41%) of participants would have made different life decisions, including lifestyle, financial, and reproductive decisions. Regarding potential harm, participants were most concerned about insurability and least concerned about removal of children's autonomy. In conclusion, NBS is highly approved of among individuals with LSDs themselves, as it would significantly eliminate diagnostic odysseys and potentially alter life planning.

Citing Articles

Obstacles to Early Diagnosis of Gaucher Disease.

Nishimura S, Ma C, Sidransky E, Ryan E Ther Clin Risk Manag. 2025; 21:93-101.

PMID: 39882275 PMC: 11776414. DOI: 10.2147/TCRM.S388266.


A Systematic Literature Review on the Global Status of Newborn Screening for Mucopolysaccharidosis II.

Ayodele O, Fertek D, Evuarherhe O, Siffel C, Audi J, Yee K Int J Neonatal Screen. 2024; 10(4).

PMID: 39449359 PMC: 11503380. DOI: 10.3390/ijns10040071.


Health service utilization, economic burden and quality of life of patients with mucopolysaccharidosis in China.

Kang Q, Fang Y, Yang Y, Li D, Zheng L, Chen X Orphanet J Rare Dis. 2024; 19(1):324.

PMID: 39243096 PMC: 11378465. DOI: 10.1186/s13023-024-03333-4.


Phenotype-Driven Molecular Genetic Test Recommendation for Diagnosing Pediatric Rare Disorders.

Chen F, Ahimaz P, Wang K, Chung W, Ta C, Weng C Res Sq. 2023; .

PMID: 38045411 PMC: 10690317. DOI: 10.21203/rs.3.rs-3593490/v1.


Newborn Screening for Fabry Disease: Current Status of Knowledge.

Gragnaniello V, Burlina A, Commone A, Gueraldi D, Puma A, Porcu E Int J Neonatal Screen. 2023; 9(2).

PMID: 37367212 PMC: 10299185. DOI: 10.3390/ijns9020031.